Radiopharm Theranostics Ltd
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation Australia
Country Australia
Business Address LEVEL 3, 62 LYGON STREET, CARLTON VIC, , 3053
Mailing Address LEVEL 3, 62 LYGON STREET, CARLTON VIC, , 3053
Phone 61 3 9824 5254
Fiscal Year End 0630
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | January 28, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 16, 2026 | View on SEC |
| 6-K Foreign company current report | January 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 8, 2026 | View on SEC |
| 424B5 Prospectus supplement | December 23, 2025 | View on SEC |
| 6-K Foreign company current report | December 19, 2025 | View on SEC |
| 6-K Foreign company current report | December 15, 2025 | View on SEC |
| 20-F/A Foreign annual report amendment | December 10, 2025 | View on SEC |
| 6-K Foreign company current report | December 4, 2025 | View on SEC |
| 6-K Foreign company current report | November 25, 2025 | View on SEC |
Annual Reports
20-F September 18, 2025
- FDA greenlit a trial for their lead breast cancer drug
- Signed a $50M partnership for prostate cancer treatment
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.